EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions

Prajakta Harish Patil, Mrunal Desai, Sumit Birangal, Gautham Shenoy Gurupur, Mahadev Rao, Anandkumar Yadav, Vishwanath Kurawattimath, Avinash Chaudhari, Tarun Sharma, Jakir Pinjari, Jagadish Puralae Channabasavaiah

European Journal of Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1007/s13318-024-00909-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Prajakta Harish Patil und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, …. Hauptthemen laut MEDLINE: Drug Interactions, Proton Pump Inhibitors, Piperazines, Purines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Indian Council of Medical Research, Manipal Academy of Higher Education, Manipal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Numerous clinical concerns have been expressed regarding the potential worsening of cyclin-dependent kinase 4/6 inhibitor effects in breast cancer patients because of co-administration of proton pump inhibitors. Hence, this study evaluated the effects of proton pump inhibitors on the pharmacokinetics of palbociclib and ribociclib in terms of cytochrome P450 (CYP) 3A4 and P-glycoprotein involvement. METHODS: The effects of omeprazole and rabeprazole on drug metabolism and efflux of these drugs were investigated using molecular docking, metabolic stability assay in rat liver microsomes, human recombinant CYP3A4 (rCYP3A4) enzymes, and Caco-2 cell monolayers, and in vivo pharmacokinetics with omeprazole and rabeprazole in (5 and 10 mg/kg) 30 min and 7 days before orally dosing palbociclib and ribociclib (10 mg/kg). RESULTS: Omeprazole and rabeprazole inhibited CYP3A4 enzyme activity in rCYP3A4 baculosomes with a 50-60% inhibition at 30 μM. Additionally, both omeprazole and rabeprazole (10 µm) significantly reduced the P-glycoprotein-mediated drug efflux of palbociclib and ribociclib. The 7-day pretreatment of omeprazole at a dose of 10 mg/kg resulted in 24% and 26% reductions in palbociclib's mean maximum plasma concentration) Cmax and area under the plasma concentration-time curve (AUC0-24 h), respectively. Palbociclib's pharmacokinetics were not significantly altered by the pretreatment with rabeprazole; however, ribociclib pharmacokinetics exhibited an 83.94% increase in AUC0-24 h. CONCLUSION: The findings indicate that long-term treatment with therapeutic doses of both omeprazole and rabeprazole can alter the pharmacokinetics of palbociclib and ribociclib. The co-administration of rabeprazole may alter the pharmacokinetics of palbociclib and ribociclib via CYP enzyme and P-glycoprotein inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsProton Pump InhibitorsPiperazinesPurinesPyridinesRabeprazoleCytochrome P-450 CYP3AOmeprazoleAminopyridinesMicrosomes, LiverCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6AnimalsHumansRatsMaleCaco-2 CellsRats, Sprague-DawleyProtein Kinase InhibitorsLiverATP Binding Cassette Transporter, Subfamily B, Member 1

Substanzen

Proton Pump InhibitorsPiperazinesribociclibPurinesPyridinesRabeprazoleCytochrome P-450 CYP3AOmeprazolepalbociclibAminopyridines

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
  • Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
  • Drug Metabolism and Pharmacokinetics, SAI Life Sciences Ltd, Hyderabad, Telangana, 500032, India.
  • Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India. jagadish.pc@manipal.edu.

Förderung

  • Indian Council of Medical Research
  • Manipal Academy of Higher Education, Manipal

Zitieren

APA

Patil, P. H., Desai, M., Birangal, S., Gurupur, G. S., Rao, M., Yadav, A., Kurawattimath, V., Chaudhari, A., Sharma, T., Pinjari, J., & Channabasavaiah, J. P. (2024). The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00909-0

Vancouver

Patil PH, Desai M, Birangal S, Gurupur GS, Rao M, Yadav A, et al. The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00909-0

BibTeX
@article{Patil2024,
  author = {Patil, Prajakta Harish and Desai, Mrunal and Birangal, Sumit and Gurupur, Gautham Shenoy and Rao, Mahadev and Yadav, Anandkumar and Kurawattimath, Vishwanath and Chaudhari, Avinash and Sharma, Tarun and Pinjari, Jakir and Channabasavaiah, Jagadish Puralae},
  title = {The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s13318-024-00909-0}
}
Kostenlos starten →